Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Clinical trial NCT07178912 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07178912
Sponsor: M.D. Anderson Cancer Center
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Phase II Clinical Trial Blinatumomab Olverembatinib Lymphoblastic Leukemia Philadelphia Chromosome Positive

Start date: 2026-08-27
Primary completion: 2031-09-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.